Guggenheim initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics initiated with an Overweight at Piper Sandler
- Buy Rating for Compass Therapeutics Driven by Promising Tovecimig Results and Strategic Pipeline
- Two new option listings on February 11th
- Optimistic Buy Rating for Compass Therapeutics Due to Promising CTX-009 Trial Results and Market Potential
- Compass Therapeutics price target raised to $8 from $7 at Jefferies
Questions or Comments about the article? Write to editor@tipranks.com